Acar B.Dağ E.Türkel Y.2020-06-252020-06-25201313002996https://hdl.handle.net/20.500.12587/2297Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome. Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy. However, the frequent adverse effects and the risk for teratogenicity have resulted in a search for alternative therapies especially in women. Lamotrigine (LTG), topiramate, and levetiracetam, have been used as monotherapy or adjunctive therapy for juvenile myoclonic epilepsy in small patient series. We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG. © 2013 OMU.eninfo:eu-repo/semantics/closedAccessAntiepileptic drugJuvenile myoclonic epilepsyLamotrigineSeizureArticle3022072082-s2.0-84886295188N/A